News

TearSolutions, Inc. Appoints Dr. Louis M Alpern to its Board of Directors

TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED) and other ocular surface related diseases, today announced that Louis M Alpern, MD, MPH, FACS, FICS has been appointed to the Company’s Board of Directors.

“Dr. Alpern brings extensive real-world clinical experience treating patients with ocular surface disease, having prescribed or trialed virtually every dry eye treatment available,” said Anil Asrani, President and CEO of TearSolutions. “Dr. Alpern has served as a Principal Investigator in over 100 ophthalmology clinical trials and we welcome his valued perspectives as we continue to advance our clinical programs.”

“I’ve seen, first-hand, the devastating impact that ocular surface disease can have on patients and their families and, as their treating physician, I shared in their frustration with currently available treatment options and the well-known problems associated with them,” said Dr. Alpern. “Given TearSolutions’ approach, the scientific rigor behind the discovery and development of their lacritin-derived peptide therapeutics and the pre-clinical and clinical data that they have generated, I believe that Lacripep has the potential to be a first-line treatment that will be broadly lauded by patients and their care-providers.”

Dr. Alpern has more than four decades of private practice and clinical trialing experience in ophthalmology. He received his Doctor of Medicine from Harvard Medical School and his Master of Public Health from the Harvard School of Public Health.

Read more here.

Recent News

07/14/2025

Terumo Health Outcomes Announces Distribution Agreement for Caretaker Medical’s VitalStream® Non-Invasive Hemodynamic Monitoring

Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), today announced a new U.S. distribution agreement with Caretaker Medical to offer Caretaker Medical’s VitalStream wearable hemodynamic monitoring platform to hospitals nationwide. This agreement is yet another step in THO’s continued effort to bring forward-looking technologies to cardiovascular care teams seeking smarter, more efficient

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,